NovoCure Ltd. clinical trials
The registry lists 28 studies whose lead sponsor is NovoCure Ltd.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 10, 2026.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 28studies on the registry
- 3open to participants now
- 2phase 3 studies under way
Get an email when these change. Save the NovoCure Ltd. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
What it is testing
The drugs NovoCure Ltd.’s studies test, most studies first; none is open now — 13 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 2
- 0 open · 2
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- pembrolizumab1 in phase 30 open · 1
- 0 open · 1
Show 3 moreShow fewer
All 28 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 319
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 1 started before 2008. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to NovoCure Ltd..
- NovoCure Ltd.19 studiesSame company
Something wrong?
- NovoCure GmbH9 studiesSame company
Something wrong?
Focus areas
Conditions NovoCure Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 28 of 28.
- LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCRecruitingNCT06216301Phase 3
Sponsor listed in the registry: NovoCure GmbH
- TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma StudyRecruitingNCT05538806
- TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)RecruitingNCT06924099
- EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaActive, not recruitingNCT06556563Phase 3
Sponsor listed in the registry: NovoCure GmbH
- Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBMCompletedNCT04471844Not applicable
- EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT06390059Phase 2
- LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06558799Phase 2
Sponsor listed in the registry: NovoCure GmbH
- Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)CompletedNCT02973789Phase 3
Sponsor listed in the registry: NovoCure GmbH
- Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)CompletedNCT03377491Phase 3
- Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)Temporarily not availableNCT07319910
Sponsor listed in the registry: NovoCure GmbH
- Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).CompletedNCT02831959Phase 3
Sponsor listed in the registry: NovoCure GmbH
- EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT04892472Phase 2
Sponsor listed in the registry: NovoCure GmbH
- Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric AdenocarcinomaCompletedNCT04281576Not applicable
- Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)CompletedNCT03606590Phase 2
- Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBMCompletedNCT04492163Phase 2
Sponsor listed in the registry: NovoCure GmbH
- Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)CompletedNCT03940196Phase 3
- TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning StudyStatus unknownNCT04717739
- Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following DischargeCompletedNCT04953234Not applicable
Sponsor listed in the registry: NovoCure GmbH
- TTFields In GErmany in Routine Clinical CareStatus unknownNCT03258021
- TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBMStatus unknownNCT03780569Not applicable
- Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)CompletedNCT02397928Phase 2
- Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)Status unknownNCT01971281Phase 1/2
- Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)CompletedNCT00916409Phase 3
- Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)Status unknownNCT01755624Phase 2
- Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)Status unknownNCT02244502Phase 1/2
- Post-approval Study of NovoTTF-100A in Recurrent GBM PatientsTerminatedNCT01756729Phase 4
- Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)CompletedNCT00379470Phase 3
- NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung CancerCompletedNCT00749346Phase 1/2